[go: up one dir, main page]

EA201170252A1 - Амидофеноксиндазолы в качестве ингибиторов c-мет - Google Patents

Амидофеноксиндазолы в качестве ингибиторов c-мет

Info

Publication number
EA201170252A1
EA201170252A1 EA201170252A EA201170252A EA201170252A1 EA 201170252 A1 EA201170252 A1 EA 201170252A1 EA 201170252 A EA201170252 A EA 201170252A EA 201170252 A EA201170252 A EA 201170252A EA 201170252 A1 EA201170252 A1 EA 201170252A1
Authority
EA
Eurasian Patent Office
Prior art keywords
amidophenoxindazoles
met inhibitors
inhibitors
met
amidophenoxy
Prior art date
Application number
EA201170252A
Other languages
English (en)
Other versions
EA018385B1 (ru
Inventor
Течао Ли
Марк Эндрю Побанс
Чуань Ших
Чжипэй У
Вэй Дженнифер Ян
Боюй Чжун
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201170252A1 publication Critical patent/EA201170252A1/ru
Publication of EA018385B1 publication Critical patent/EA018385B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Согласно настоящему изобретению предложены амидофеноксииндазольные соединения, подходящие для применения в лечении рака.
EA201170252A 2008-07-24 2009-07-15 АМИДОФЕНОКСИИНДАЗОЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-Met EA018385B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8329408P 2008-07-24 2008-07-24
US8508208P 2008-07-31 2008-07-31
US10865908P 2008-10-27 2008-10-27
PCT/US2009/050640 WO2010011538A1 (en) 2008-07-24 2009-07-15 Amidophenoxyindazoles useful as inhibitors of c-met

Publications (2)

Publication Number Publication Date
EA201170252A1 true EA201170252A1 (ru) 2011-06-30
EA018385B1 EA018385B1 (ru) 2013-07-30

Family

ID=41010247

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170252A EA018385B1 (ru) 2008-07-24 2009-07-15 АМИДОФЕНОКСИИНДАЗОЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-Met

Country Status (35)

Country Link
US (2) US8030302B2 (ru)
EP (1) EP2310382B1 (ru)
JP (1) JP5414794B2 (ru)
KR (1) KR101334456B1 (ru)
CN (1) CN102105462B (ru)
AR (1) AR074632A1 (ru)
AT (1) ATE546444T1 (ru)
AU (1) AU2009274256B2 (ru)
BR (1) BRPI0916286B8 (ru)
CA (1) CA2731773C (ru)
CL (1) CL2011000134A1 (ru)
CO (1) CO6351737A2 (ru)
CR (1) CR20110046A (ru)
CY (1) CY1112595T1 (ru)
DK (1) DK2310382T3 (ru)
DO (1) DOP2011000009A (ru)
EA (1) EA018385B1 (ru)
EC (1) ECSP11010778A (ru)
ES (1) ES2379587T3 (ru)
HR (1) HRP20120202T1 (ru)
IL (1) IL210490A (ru)
JO (1) JO2788B1 (ru)
MA (1) MA32594B1 (ru)
MX (1) MX2011000925A (ru)
MY (1) MY163852A (ru)
NZ (1) NZ590013A (ru)
PE (1) PE20110150A1 (ru)
PL (1) PL2310382T3 (ru)
PT (1) PT2310382E (ru)
RS (1) RS52261B (ru)
SI (1) SI2310382T1 (ru)
SV (1) SV2011003816A (ru)
TW (1) TWI365185B (ru)
WO (1) WO2010011538A1 (ru)
ZA (1) ZA201100219B (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110075016A (ko) 2008-10-14 2011-07-05 닝 시 화합물 및 사용 방법
EP2408300B1 (en) 2009-03-21 2016-05-11 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
CA2820709C (en) 2011-02-28 2016-02-16 Sunshine Lake Pharma Co., Ltd. Substituted quinoline compounds and methods of use
JP5970003B2 (ja) * 2011-03-04 2016-08-17 ローカス ファーマシューティカルズ インコーポレイテッド アミノピラジン化合物
KR20130118612A (ko) * 2012-04-20 2013-10-30 (주)네오믹스 신규한 아미노피리딘 유도체 및 이의 용도
CN104334581B (zh) * 2012-05-09 2018-02-02 伊莱利利公司 抗‑c‑Met抗体
EP2961744B1 (en) * 2013-02-27 2017-06-28 Array Biopharma, Inc. Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof
CN104140393B (zh) * 2013-12-10 2016-09-21 郑州泰基鸿诺医药股份有限公司 一种芳环/芳杂环叔丁醇酯类化合物的制备方法
US9718841B2 (en) 2014-04-22 2017-08-01 Calitor Sciences, Llc Bicyclic pyrazolone compounds and methods of use
TW201716085A (zh) * 2015-08-12 2017-05-16 應克隆公司 癌症之組合療法
EP3442573A1 (en) * 2016-04-15 2019-02-20 Eli Lilly and Company Combination of ramucirumab and merestinib for use in treatment of colorectal cancer
ES3008636T3 (en) 2016-06-02 2025-03-24 Immunocore Ltd Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein
EP3490676A1 (en) * 2016-07-29 2019-06-05 Eli Lilly and Company Combination therapy with merestinib and anti-pd-l1 or anti-pd-1 inhibitors for use in the treatment of cancer
CN108069938A (zh) * 2016-11-15 2018-05-25 中国药科大学 2,4-二取代吡啶类化合物及其制备方法和应用
US20210283249A1 (en) 2016-11-16 2021-09-16 Eli Lilly And Company Combination therapy for cancer with exon 14 skipping mutation(s) or exon 14 skipping phenotype
WO2018093654A1 (en) 2016-11-16 2018-05-24 Eli Lilly And Company Treatment of cancer with exon 14 skipping mutation(s) or exon 14 skipping phenotype
CN107382968A (zh) * 2017-07-06 2017-11-24 北京万全德众医药生物技术有限公司 一种吲哚类c‑Met抑制剂的制备方法
CN107311983A (zh) * 2017-07-06 2017-11-03 北京万全德众医药生物技术有限公司 吲哚类小分子c‑met抑制剂
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
EP3480201A1 (en) 2017-11-06 2019-05-08 Oncostellae, S.L. New analogs as androgen receptor and glucocorticoid receptor modulators
JP7377798B2 (ja) 2017-11-24 2023-11-10 南京明徳新薬研発有限公司 ｃ－ＭＥＴ／ＡＸＬ阻害剤としてのウラシル系化合物
CN110041316B (zh) * 2018-01-17 2022-04-19 药捷安康(南京)科技股份有限公司 Tam家族激酶/和csf1r激酶抑制剂及其用途
CN111295386B (zh) 2018-03-08 2022-09-06 伟迈可生物有限公司 噻吩并吡啶衍生物及含有该衍生物的药物组合物
CA3109891A1 (en) * 2018-08-24 2020-02-27 Nanjing Transthera Biosciences Co., Ltd. Quinoline derivative inhibitor: tam, ntrk, and csf1r kinases
JP7443373B2 (ja) * 2018-09-03 2024-03-05 タイリガンド バイオサイエンス（シャンハイ）リミテッド 抗がん性薬物としてのｔｒｋ阻害剤
CN112771053A (zh) 2019-09-06 2021-05-07 伟迈可生物有限公司 基于生物标志物的治疗组合物
CN117355533A (zh) * 2021-06-22 2024-01-05 株式会社Lg化学 作为蛋白激酶抑制剂的新型化合物
WO2023110936A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Reversible macrocyclic kinase inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO155316C (no) * 1982-04-23 1987-03-11 Sintef Fremgangsmaate for fremstilling av magnetiske polymerpartikler.
US5484681A (en) * 1994-10-31 1996-01-16 Xerox Corporation Conductive composite particles and processes for the preparation thereof
IL114149A0 (en) * 1995-06-14 1995-10-31 Yeda Res & Dev Modified avidin and streptavidin molecules and use thereof
US5747577A (en) * 1995-12-27 1998-05-05 Xerox Corporation Conductive particles containing carbon black and processes for the preparation thereof
DE10046029A1 (de) 2000-09-18 2002-03-28 Bayer Ag Indazole
ES2268015T3 (es) * 2001-05-18 2007-03-16 Srl, Inc. Procedimiento de inmunoensayo.
US6956084B2 (en) * 2001-10-04 2005-10-18 Bridgestone Corporation Nano-particle preparation and applications
JP2004067703A (ja) * 2002-04-24 2004-03-04 Japan Science & Technology Corp 架橋ポリマー、微粒子および製造方法
US7192780B2 (en) * 2002-10-23 2007-03-20 Evident Technologies Fluorescent lifetime biological detection and imaging using water-stable semiconductor nanocrystals
EP1562935B1 (de) 2002-10-28 2006-09-06 Bayer HealthCare AG Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
DE602004010525T2 (de) * 2003-07-17 2008-11-27 Invitrogen Dynal As Verfahren zur herstellung von ummantelten magnetischen teilchen
US7163998B2 (en) * 2003-09-09 2007-01-16 Eastman Kodak Company Stabilized polymer beads and method of preparation
US7173031B2 (en) * 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
ES2612377T3 (es) 2005-12-21 2017-05-16 Janssen Pharmaceutica N.V. Triazolopiridazinas como moduladores de tirosina cinasas
RU2008139599A (ru) * 2006-03-07 2010-04-20 Эррэй Биофарма Инк. (Us) Гетеробициклические производные пиразола и способы их применения
JP2009542862A (ja) * 2006-06-29 2009-12-03 インヴィトロジェン ダイナル エーエス マルチブロックポリマーを含む粒子
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8507489B2 (en) 2006-10-23 2013-08-13 Sgx Pharmaceuticals, Inc. Bicyclic triazoles as protein kinase modulators
WO2009003084A1 (en) 2007-06-27 2008-12-31 Arkema Inc. Process for the manufacture of hydrofluoroolefins

Also Published As

Publication number Publication date
AU2009274256A1 (en) 2010-01-28
TW201006817A (en) 2010-02-16
KR20110022691A (ko) 2011-03-07
KR101334456B1 (ko) 2013-11-29
JP2011529054A (ja) 2011-12-01
AU2009274256B2 (en) 2013-07-11
CN102105462A (zh) 2011-06-22
PT2310382E (pt) 2012-04-11
JO2788B1 (en) 2014-03-15
CL2011000134A1 (es) 2011-07-08
MA32594B1 (fr) 2011-09-01
BRPI0916286B8 (pt) 2021-05-25
ECSP11010778A (es) 2011-02-28
NZ590013A (en) 2012-06-29
ATE546444T1 (de) 2012-03-15
HRP20120202T1 (hr) 2012-03-31
JP5414794B2 (ja) 2014-02-12
MX2011000925A (es) 2011-03-21
PE20110150A1 (es) 2011-03-07
EP2310382A1 (en) 2011-04-20
CY1112595T1 (el) 2016-02-10
DK2310382T3 (da) 2012-03-26
HK1155172A1 (en) 2012-05-11
RS52261B (sr) 2012-10-31
DOP2011000009A (es) 2011-03-31
WO2010011538A1 (en) 2010-01-28
ZA201100219B (en) 2012-06-27
IL210490A (en) 2013-06-27
AR074632A1 (es) 2011-02-02
MY163852A (en) 2017-10-31
PL2310382T3 (pl) 2012-07-31
IL210490A0 (en) 2011-03-31
SV2011003816A (es) 2011-03-17
CN102105462B (zh) 2014-07-23
CA2731773A1 (en) 2010-01-28
BRPI0916286B1 (pt) 2019-10-08
EA018385B1 (ru) 2013-07-30
SI2310382T1 (sl) 2012-04-30
US20100022529A1 (en) 2010-01-28
CA2731773C (en) 2013-03-12
US8030302B2 (en) 2011-10-04
TWI365185B (en) 2012-06-01
EP2310382B1 (en) 2012-02-22
ES2379587T3 (es) 2012-04-27
CR20110046A (es) 2011-04-27
USRE43878E1 (en) 2012-12-25
CO6351737A2 (es) 2011-12-20

Similar Documents

Publication Publication Date Title
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
EA201171367A1 (ru) Винилиндазолильные соединения
EA201170521A1 (ru) Новые соединения
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
MA32562B1 (fr) Composes organiques pour la cicatrisation de lesion
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
EA201170832A1 (ru) Пуриновые соединения
CL2011000191A1 (es) Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
EA201400178A1 (ru) Лечение рака молочной железы
MX354402B (es) Inhibidores de molecula pequeña del dominio de homologia de pleckstrin y metodos para usar los mismos.
EA201170227A1 (ru) Имидазолкарбоксамиды
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
EA201270049A1 (ru) Дизамещенные фталазиновые антагонисты пути hedgehog
EA200901074A1 (ru) Лечение метастатической стадии рака предстательной железы дегареликсом
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
ECSP088536A (es) DERIVADOS DE PIRIDO-, PIRAZO- Y PIRIMIDO-PIRIMIDINA COMO INHIBIDORES DE mTOR
EA201071248A1 (ru) Дизамещенные фталазиновые антагонисты пути hedgehog
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
EA201290642A1 (ru) Соединения и способы
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней
BRPI0814772A2 (pt) Indazóis substituídos por 5-piridinona

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KG MD TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ TJ

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM KZ RU